Pharma & Healthcare Funding Drops 85.83% in February 2025

This marks a steep decline from $300 million in January 2025, representing a 78.86% drop compared to $201 million in February 2024.

Funding in the healthcare and pharma sector saw a significant drop of 85.83% in February 2025, falling to $42.5 million.

This marks a steep decline from $300 million in January 2025 and represents a 78.86% drop compared to $201 million in February 2024, according to a report by Tracxn.

The report highlights that February 2025 was among the sector's lowest-funded months in the past year.

Early-Stage Rounds Dominate Investments

Despite the decline, early-stage funding accounted for 85.1% of the total investment, raising $34.6 million in February. Seed-stage investments contributed $7.87 million, making up 18.5% of the total funding.

Among the notable funding rounds, MOC secured $18 million, while Apex Kidney Care raised $9 million. Key investors during this period included Elevation Capital, Endiya Partners, and Good Capital.

The decline in funding reflects a cautious investment environment in the healthcare and pharma sector. While early-stage investments continue to attract funding, the significant drop in overall investment levels raises concerns about sustained capital flow in the industry.

Stay tuned for more such updates on Digital Health News